Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SCYNEXIS ( (SCYX) ) has issued an announcement.
On April 16, 2026, SCYNEXIS director Steven C. Gilman notified the company that he will retire from the Board and will not stand for reelection at the 2026 annual meeting of stockholders. His term will end at the conclusion of that meeting, at which point he will also step down as Chair of the Compensation Committee and as a member of the Nominating and Corporate Governance Committee.
SCYNEXIS emphasized that Dr. Gilman’s decision to retire was not due to any disagreement with management, company strategy, or Board practices. The orderly transition suggests continuity in corporate governance and minimizes concerns for investors about potential internal conflicts or strategic rifts at the board level.
The most recent analyst rating on (SCYX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on SCYNEXIS stock, see the SCYX Stock Forecast page.
Spark’s Take on SCYX Stock
According to Spark, TipRanks’ AI Analyst, SCYX is a Neutral.
The score is held back primarily by weak and volatile operating performance with still-negative free cash flow, despite a substantially improved balance sheet. Technicals are moderately positive with price above key moving averages and a positive MACD, and recent corporate events add support via new pipeline focus and extended runway. Valuation is constrained by losses (negative P/E) and no dividend support.
To see Spark’s full report on SCYX stock, click here.
More about SCYNEXIS
SCYNEXIS, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel anti-infective therapies. The company targets serious and often drug-resistant infections, aiming to address unmet medical needs in infectious disease treatment across hospital and community settings.
Average Trading Volume: 620,580
Technical Sentiment Signal: Buy
Current Market Cap: $49.58M
For detailed information about SCYX stock, go to TipRanks’ Stock Analysis page.